Ixekizumab demonstrates strong response rates in juvenile arthritis. Read more about the latest trial findings.
Last year, medical expenses for mild diseases were estimated to reach 20 trillion won. According to data from the Health Insurance Review & Assessment Service’s ‘Health Insurance Claims Status for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results